Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. develops clinical-stage Alzheimer’s disease therapeutics that target toxic soluble amyloid beta oligomers. The company’s recurring updates center on sabirnetug (ACU193), a humanized monoclonal antibody program, the ALTITUDE-AD and INTERCEPT-AD clinical study framework, and research on biomarkers and antibody selectivity.
Company news also covers Enhanced Brain Delivery (EBD™) work using transferrin-receptor-targeting blood-brain barrier technology, subcutaneous formulation research using ENHANZE® drug delivery technology, collaborations, conference presentations, operating results, financing activity, and management participation in health care and CNS investor events.
JCR Pharmaceuticals (TSE:4552) and Acumen Pharmaceuticals (NASDAQ: ABOS) expanded their Alzheimer’s collaboration as Acumen exercised its exclusive option to develop, manufacture and commercialize up to two blood-brain barrier-penetrating candidates enabled by J-Brain Cargo®.
Acumen targets an IND filing in mid-2027. JCR receives an option payment and may earn up to USD 555 million in development and sales milestones plus tiered royalties. Non-clinical mouse data showed increased brain exposure while preserving AβO selectivity, and J-Brain Cargo® is clinically validated via IZCARGO™. The impact is already reflected in JCR’s fiscal 2027 earnings forecast.
Acumen Pharmaceuticals (NASDAQ: ABOS) nominated two Enhanced Brain Delivery™ (EBD™) development candidates, ACU301 and ACU401, for Alzheimer’s disease, exercising its option under a license with JCR Pharmaceuticals.
Candidates combine Acumen’s AβO-selective antibodies with JCR’s J-Brain Cargo® to enhance blood-brain barrier penetration; IND-enabling work is underway targeting mid-2027 IND submissions.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported first quarter 2026 results and Alzheimer’s pipeline updates. Cash, cash equivalents and marketable securities were $128.4 million as of Mar. 31, 2026, supported by a $35.75 million private placement, funding operations into early 2027.
R&D expenses were $16.5 million versus $25.3 million a year ago; G&A was $4.7 million versus $5.1 million. Net loss was $20.7 million, improved from $28.8 million. Topline Phase 2 ALTITUDE-AD results for sabirnetug in early Alzheimer’s are expected in late 2026, with an EBD program IND targeted for mid-2027.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026 at 8:55 a.m. PT / 11:55 a.m. ET.
The session will be webcast live and archived for 90 days under the Investors tab at the company website.
Acumen Pharmaceuticals (NASDAQ: ABOS) will report first quarter 2026 financial results on Tuesday, May 12, 2026. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Investors must register in advance to receive dial-in numbers and PIN; the webcast and an archived audio recording will be available on the company's Investors website for at least 30 days.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported 2025 results and a business update on Mar 26, 2026, highlighting clinical progress for sabirnetug and advancement of an Enhanced Brain Delivery (EBD) program.
Key items: $35.75M private placement for EBD candidates, $116.9M cash as of Dec 31, 2025 (runway into early 2027), topline ALTITUDE-AD Phase 2 results expected late 2026, and an IND target for an EBD lead candidate in mid-2027. R&D spend rose to $104.9M; net loss was $121.3M for 2025.
Acumen Pharmaceuticals (NASDAQ: ABOS) will report fourth quarter and year-end 2025 financial results on March 26, 2026 and will host a conference call and live audio webcast at 8:00 a.m. ET.
According to the company, registration is required for dial-in details, the live webcast link is provided, and an archived webcast will be available for at least 30 days in Investors on www.acumenpharm.com.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new preclinical and biomarker data at AD/PD 2026 (March 17-21) on enhanced brain delivery, NULISAseq biomarker profiling, and novel anti-amyloid beta oligomer antibodies. Key findings: TfR-targeted bispecifics increased sabirnetug brain exposure, NULISAseq measured 127 CNS proteins, and ACU234 showed ~21,000-fold oligomer selectivity.
The data support further characterization and integration with ongoing Phase 2 ALTITUDE‑AD and prior Phase 1 INTERCEPT‑AD results.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced a $35.75 million private placement at $3.30 per share to fund its Enhanced Brain Delivery (EBD™) program and general corporate purposes, with closing expected on or about March 16, 2026.
Preclinical EBD data show development candidates achieved 14–40x higher brain exposure in non-human primates, low anemia signal in hematology, stability supporting subcutaneous dosing, and an IND target of mid-2027.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026 at 11:00 a.m. ET. The company is a clinical-stage biopharmaceutical developer targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease. The live webcast is available under the Investors tab on the company website and will be archived for 90 days.